Current Treatment Options in Neurology

, Volume 15, Issue 3, pp 316–327

Gliomas in Children


Opinion statement

Gliomas are the most common brain tumor in children and represent nearly 50 % of all pediatric central nervous system (CNS) tumors. They are a heterogeneous group of diseases, ranging from highly malignant and frequently fatal to histologically benign and curable by surgery alone. A uniform treatment approach to these tumors is not practical, due to their histological and biological heterogeneity. Low-grade gliomas (LGGs) are best treated with maximally safe surgical resection, generally achievable for hemispheric or cerebellar locations. Patients with deep midline, optic pathway/hypothalamic, and brain stem locations should undergo subtotal resection or biopsy only. If a complete resection is not feasible, subtotal resection followed by adjuvant chemotherapy or radiotherapy is the standard approach; however, observation alone with serial neuroimaging is used in some asymptomatic, surgically inaccessible lesions. Chemotherapy is used first-line in cases of residual or progressive disease, to avoid or delay radiation therapy and its associated side effects. Regimens demonstrating objective responses and increased progression free survival (PFS) include carboplatin and vincristine (CV), thioguanine/procarbazine/CCNU/vincristine (TPCV), or weekly vinblastine. High-grade gliomas (HGGs) are less common in children than in adults, though are similar in their aggressive clinical behavior, resistance to therapy, and dismal outcomes. There is not a single “standard of care” therapy for non-metastatic HGGs, but generally accepted is an aggressive attempt at a complete surgical resection, followed by multimodality therapy with focal radiation and chemotherapy. The use of temozolomide (TMZ) during and following radiotherapy is common, though it appeared not to improve the outcome in a cooperative group clinical trial when compared to an historical control cohort. The angiogenesis inhibitor bevacizumab, used alone or in combination with irinotecan, is also commonly used as maintenance therapy after radiation. Current trials are prospectively comparing TMZ to newer agents (vorinostat, bevacizumab) in a randomized phase II trial. Brainstem gliomas are a unique category of childhood gliomas. Approximately 80 % of childhood brainstem gliomas arise within the pons as diffuse intrinsic pontine gliomas (DIPG). When biopsied, these are usually HGGs and carry a dismal prognosis. Standard therapy is focal radiation (54–58 Gy), preferably on a clinical trial testing concurrent chemotherapy or biologic agent. No standard chemotherapy agent has impacted survival. The remaining 20 % of brainstem gliomas are low-grade, arise in the midbrain, dorsal medulla, or cervicomedullary junction, and are indolent in nature with a much better prognosis. Improvement in the outcome of all childhood gliomas will require increased knowledge of the underlying biology of these tumors, in order to treat with more biologically based and precise therapies.


Brain tumor Childhood Glioma Low-grade glioma High-grade glioma Brain stem glioma Diffuse intrinsic pontine glioma Chemotherapy Targeted therapy Treatment Radiation Surgery Proton Neurocognitive Children Pediatrics 

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Dolecek TA, Propp JM, Stroup NE, et al. Central brain tumor registry of the United States. 2012. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012;14(sup 5):v1–49.PubMedCrossRefGoogle Scholar
  2. 2.
    Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Sievert AJ, Jackson EM, Gai X, et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol. 2009;19(3):449–58.PubMedCrossRefGoogle Scholar
  4. 4.
    Kluwe L, Hagel C, Tatagiba M, et al. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J Neuropathol Exp Neurol. 2001;60(9):917–20.PubMedGoogle Scholar
  5. 5.
    Lau N, Feldkamp MM, Roncari L, et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol. 2000;59(9):759–67.PubMedGoogle Scholar
  6. 6.
    Broniscer A. Past, present, and future strategies in the treatment of high-grade glioma in children. Cancer Invest. 2006;24(1):77–81.PubMedCrossRefGoogle Scholar
  7. 7.•
    Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol. 2011;13(3):317–23. This non-randomized trial examined the use of temozolomide with radiation for newly diagnosed HGG. Major findings of this trial include that temozolomide may not be as efficacious in childhood HGG as it is in adult HGG and underscores the differences. It also highlighted the perils of using historical controls.PubMedCrossRefGoogle Scholar
  8. 8.
    Fangusaro J. Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology. Front Oncol. 2012;2:105.PubMedCrossRefGoogle Scholar
  9. 9.
    Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28(18):3061–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Pollack IF, Hamilton RL, James CD, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children’s Cancer Group 945 cohort. J Neurosurg. 2006;105(5 Suppl):418–24.PubMedGoogle Scholar
  11. 11.
    Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Liang ML, Ma J, Ho M, et al. Tyrosine kinase expression in pediatric high grade astrocytoma. J Neurooncol. 2008;87(3):247–53.PubMedCrossRefGoogle Scholar
  13. 13.
    Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012;44(3):251–3.PubMedCrossRefGoogle Scholar
  15. 15.••
    Paugh BS, Broniscer A, Qu C, et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol. 2011;29(30):3999–4006. This paper on genome-wide studies in a large cohort of DIPG samples identifies relevant genomic alterations likely important in tumorigenesis and highlights the distinct biology of DIPG compared to HGG. This study also raises awareness of the importance of collecting tumor tissue for DIPG.PubMedCrossRefGoogle Scholar
  16. 16.
    Sanders RP, Kocak M, Burger PC, et al. High-grade astrocytoma in very young children. Pediatr Blood Cancer. 2007;49(7):888–93.PubMedCrossRefGoogle Scholar
  17. 17.
    Pollack IF, Hamilton RL, Sobol RW, et al. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol. 2006;24(21):3431–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Pollack IF, Hamilton RL, Sobol RW, et al. Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2010;55(6):1066–71.PubMedCrossRefGoogle Scholar
  19. 19.
    Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Jansen MH, van Vuurden DG, Vandertop WP, et al. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev. 2012;38(1):27–35.PubMedCrossRefGoogle Scholar
  21. 21.
    Grill J, Puget S, Andreiuolo F, et al. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer. 2012;58(4):489–91.PubMedCrossRefGoogle Scholar
  22. 22.
    Roujeau T, Machado G, Garnett MR, et al. Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg. 2007;107(1 Suppl):1–4.PubMedGoogle Scholar
  23. 23.
    Buczkowicz P, Zarghooni M, Bartels U, et al. Aurora Kinase B. Is a Potential Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma. Brain Pathol. 2012.Google Scholar
  24. 24.
    Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010;28(8):1337–44.PubMedCrossRefGoogle Scholar
  25. 25.
    Morita N, Harada M, Otsuka H, et al. Clinical application of MR spectroscopy and imaging of brain tumor. Magn Reson Med Sci. 2010;9(4):167–75.PubMedCrossRefGoogle Scholar
  26. 26.
    Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol. 2004;25(2):214–21.PubMedGoogle Scholar
  27. 27.
    Hipp SJ, Steffen-Smith E, Hammoud D, et al. Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging. Neuro Oncol. 2011;13(8):904–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Perilongo G, Garre ML, Giangaspero F. Low-grade gliomas and leptomeningeal dissemination: a poorly understood phenomenon. Childs Nerv Syst. 2003;19(4):197–203.PubMedGoogle Scholar
  29. 29.
    Sutton LN, Cnaan A, Klatt L, et al. Postoperative surveillance imaging in children with cerebellar astrocytomas. J Neurosurg. 1996;84(5):721–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Shaw EG, Wisoff JH. Prospective clinical trials of intracranial low-grade glioma in adults and children. Neuro Oncol. 2003;5(3):153–60.PubMedCrossRefGoogle Scholar
  31. 31.
    Selvapandian S. Endoscopic management of thalamic gliomas. Minim Invasive Neurosurg. 2006;49(4):194–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Li KW, Roonprapunt C, Lawson HC, et al. Endoscopic third ventriculostomy for hydrocephalus associated with tectal gliomas. Neurosurg Focus. 2005;18(6A):E2.PubMedGoogle Scholar
  33. 33.
    Finlay JL, Boyett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens cancer group. J Clin Oncol. 1995;13(1):112–23.PubMedGoogle Scholar
  34. 34.
    Doxey D, Bruce D, Sklar F, et al. Posterior fossa syndrome: identifiable risk factors and irreversible complications. Pediatr Neurosurg. 1999;31(3):131–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Listernick R, Ferner RE, Liu GT, et al. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol. 2007;61(3):189–98.PubMedCrossRefGoogle Scholar
  36. 36.
    Armstrong GT, Liu Q, Yasui Y, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009;101(13):946–58.PubMedCrossRefGoogle Scholar
  37. 37.
    Cotter SE, McBride SM, Yock TI. Proton radiotherapy for solid tumors of childhood. Technol Cancer Res Treat. 2012;11(3):267–78.PubMedCrossRefGoogle Scholar
  38. 38.
    Hug EB, Muenter MW, Archambeau JO, et al. Conformal proton radiation therapy for pediatric low-grade astrocytomas. Strahlenther Onkol. 2002;178(1):10–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Gnekow AK, Kortmann RD, Pietsch T, et al. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy—report from the multicenter treatment study for children and adolescents with a low grade glioma—HIT-LGG 1996—of the Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr. 2004;216(6):331–42.PubMedCrossRefGoogle Scholar
  40. 40.
    Gnekow AK, Falkenstein F, von Hornstein S, et al. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol. 2012;14(10):1265–84.PubMedCrossRefGoogle Scholar
  41. 41.
    Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86(5):747–54.PubMedCrossRefGoogle Scholar
  42. 42.
    Merchant TE, Kun LE, Wu S, et al. Phase II trial of conformal radiation therapy for pediatric low-grade glioma. J Clin Oncol. 2009;27(22):3598–604.PubMedCrossRefGoogle Scholar
  43. 43.
    Dufour C, Grill J, Lellouch-Tubiana A, et al. High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol. Eur J Cancer. 2006;42(17):2939–45.PubMedCrossRefGoogle Scholar
  44. 44.
    Massimino M, Cohen KJ, Finlay JL. Is there a role for myeloablative chemotherapy with autologous hematopoietic cell rescue in the management of childhood high-grade astrocytomas? Pediatr Blood Cancer. 2010;54(4):641–3.PubMedCrossRefGoogle Scholar
  45. 45.
    Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7(3):241–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Packer RJ, Krailo M, Mehta M, et al. A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. Cancer. 2005;104(9):1968–74.PubMedCrossRefGoogle Scholar
  47. 47.
    Prados MD, Wara WM, Edwards MS, et al. The treatment of brain stem and thalamic gliomas with 78 Gy of hyperfractionated radiation therapy. Int J Radiat Oncol Biol Phys. 1995;32(1):85–91.PubMedCrossRefGoogle Scholar
  48. 48.
    Sanghavi SN, Needle MN, Krailo MD, et al. A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children’s Cancer Group-0952. Neuro Oncol. 2003;5(1):8–13.PubMedGoogle Scholar
  49. 49.
    Prados MD, Edwards MS, Rabbitt J, et al. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol. 1997;32(3):235–41.PubMedCrossRefGoogle Scholar
  50. 50.••
    Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(21):2641–7. This large, prospective randomized trial compares the use of carboplatin/vincristine and TPCV for treating LGG in children under 10 years of age, and validates the use of chemotherapy to delay or defer RT.PubMedCrossRefGoogle Scholar
  51. 51.
    Massimino M, Spreafico F, Cefalo G, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002;20(20):4209–16.PubMedCrossRefGoogle Scholar
  52. 52.
    Massimino M, Spreafico F, Riva D, et al. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol. 2010;100(1):65–71.PubMedCrossRefGoogle Scholar
  53. 53.
    Lafay-Cousin L, Holm S, Qaddoumi I, et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer. 2005;103(12):2636–42.PubMedCrossRefGoogle Scholar
  54. 54.
    Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012;30(12):1358–63.PubMedCrossRefGoogle Scholar
  55. 55.
    Hwang EI, Jakacki RI, Fisher MJ, et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer. 2012. doi:10.1002/pbc.24297.
  56. 56.
    Lashkari HP, Saso S, Moreno L, et al. Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. J Neurooncol. 2011;105(2):135–47.PubMedCrossRefGoogle Scholar
  57. 57.
    Sposto R, Ertel IJ, Jenkin RD, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol. 1989;7(2):165–77.PubMedCrossRefGoogle Scholar
  58. 58.
    Boyett J, Yates A, Gilles FH, et al. When is a high-grade astrocytoma (HGA) not a HGA? Results of a central review of 226 cases of anaplastic astrocytoma (AA), glioblastoma multiforme (GBM), and other-HGA (OTH-HGA) by five neuropathologists. Proc Am Soc Clin Oncol. 1998;17:526a.Google Scholar
  59. 59.
    Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.PubMedCrossRefGoogle Scholar
  60. 60.
    Soffietti R, Trevisan E, Bertero L, et al. Anti-angiogenic approaches to malignant gliomas. Curr Cancer Drug Targets. 2012;12(3):279–88.PubMedCrossRefGoogle Scholar
  61. 61.
    Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28(18):3069–75.PubMedCrossRefGoogle Scholar
  62. 62.
    Parekh C, Jubran R, Erdreich-Epstein A, et al. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. J Neurooncol. 2011;103(3):673–80.PubMedCrossRefGoogle Scholar
  63. 63.
    Narayana A, Kunnakkat S, Chacko-Mathew J, et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol. 2010;12(9):985–90.PubMedCrossRefGoogle Scholar
  64. 64.
    Sweet JA, Feinberg ML, Sherman JH. The role of avastin in the management of recurrent glioblastoma. Neurosurg Clin N Am. 2012;23(2):331–41. x.Google Scholar
  65. 65.
    Finlay JL, Dhall G, Boyett JM, et al. Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2008;51(6):806–11.PubMedCrossRefGoogle Scholar
  66. 66.
    Bradley KA, Zhou T, McNall-Knapp RY, et al. Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children’s oncology group phase 2 study. Int J Radiat Oncol Biol Phys. 2013;85(1):e55–60.PubMedCrossRefGoogle Scholar
  67. 67.
    Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007;9(2):145–60.PubMedCrossRefGoogle Scholar
  68. 68.
    Haas-Kogan DA, Banerjee A, Poussaint TY, et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol. 2011;13(3):298–306.PubMedCrossRefGoogle Scholar
  69. 69.
    Pollack IF, Stewart CF, Kocak M, et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 2011;13(3):290–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Broniscer A, Baker JN, Tagen M, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol. 2010;28(31):4762–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Okada H, Low KL, Kohanbash G, et al. Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neurooncol. 2008;88(3):245–50.PubMedCrossRefGoogle Scholar
  72. 72.
    Li G, Mitra SS, Monje M, et al. Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. J Neurooncol. 2012;108(3):395–402.PubMedCrossRefGoogle Scholar
  73. 73.
    Yalon M, Rood B, Macdonald TJ, et al. A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Pediatr Blood Cancer. 2013;60(1):71–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Sands SA, Zhou T, O’Neil SH, et al. Long-term follow-up of children treated for high-grade gliomas: children’s oncology group L991 final study report. J Clin Oncol. 2012;30(9):943–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Cappelli C, Grill J, Raquin M, et al. Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era. Arch Dis Child. 1998;79(4):334–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Pollack IF, Claassen D. al-Shboul Q, et al. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J Neurosurg. 1995;82(4):536–47.PubMedCrossRefGoogle Scholar
  77. 77.
    Sutton LN, Molloy PT, Sernyak H, et al. Long-term outcome of hypothalamic/chiasmatic astrocytomas in children treated with conservative surgery. J Neurosurg. 1995;83(4):583–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Lacaze E, Kieffer V, Streri A, et al. Neuropsychological outcome in children with optic pathway tumours when first-line treatment is chemotherapy. Br J Cancer. 2003;89(11):2038–44.PubMedCrossRefGoogle Scholar
  79. 79.
    Campen CJ, Kranick SM, Kasner SE, et al. Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. Stroke. 2012;43(11):3035–40.PubMedCrossRefGoogle Scholar
  80. 80.
    Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006;24(33):5277–82.PubMedCrossRefGoogle Scholar
  81. 81.
    Partap S. Stroke and cerebrovascular complications in childhood cancer survivors. Semin Pediatr Neurol. 2012;19(1):18–24.PubMedCrossRefGoogle Scholar
  82. 82.
    Mostoufi-Moab S, Grimberg A. Pediatric brain tumor treatment: growth consequences and their management. Pediatr Endocrinol Rev. 2010;8(1):6–17.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of Oncology and Center for Childhood Cancer ResearchChildren’s Hospital of PhiladelphiaPhiladelphiaUSA
  2. 2.Department of PediatricsPerelman School of Medicine at the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations